NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Valuation Check After New Drug Approvals And US$1b Cell Therapy Investment
Johnson & Johnson (JNJ) has packed several clinically focused announcements into February, including new subcutaneous dosing approvals for RYBREVANT, long term TREMFYA data in ulcerative colitis, and a more than US$1b U.S. cell therapy manufacturing build out.
See our latest analysis for Johnson & Johnson.
All these February announcements around RYBREVANT, TREMFYA and new U.S. manufacturing capacity are landing at a time when momentum in Johnson & Johnson’s shares is strong, with an 11.7% 1...